Tags

Type your tag names separated by a space and hit enter

Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson's disease.

Abstract

PURPOSE

Incidence of hip fractures among elderly patients with Parkinson's disease is high. Recent studies have found that levodopa induces hyperhomocysteinemia in Parkinson's disease. Hyperhomocysteinemia is considered to be a risk factor for osteoporotic fractures in elderly men and women. Very high plasma homocysteine levels are a feature of homocystinuria, characterized by the early onset of osteoporosis. To determine the association between plasma homocysteine concentration and the risk of hip fracture in Parkinson's disease patients receiving levodopa, we prospectively studied a cohort of elderly women with Parkinson's disease.

METHODS

We studied 199 elderly women with Parkinson's disease receiving levodopa therapy, from whom blood samples had been obtained to measure plasma homocysteine. Age-adjusted incidence rates of hip fractures were calculated for quartiles of plasma homocysteine concentrations. Cox proportional-hazard regression was used to calculate hazard ratios for quartiles of homocysteine values.

RESULTS

The mean duration of follow-up was 4.9 years. Hip fractures occurred in 66 patients. The age-adjusted incidence rates per 1000 person-years for hip fractures, from the lowest to the highest quartile of plasma homocysteine levels, were 1.59 (95% confidence interval [CI], 1.01-2.24), 1.57 (95% CI, 0.98-2.19), 1.21 (95% CI, 0.61-1.72), and 26.98 (95% CI, 16.48-37.24). The risk of hip fractures was greater in the highest quartile than that in the lowest, and the risk was almost 2.4 times higher.

CONCLUSION

These findings suggest that the homocysteine concentration is an important risk factor for hip fractures in Parkinson's disease patients receiving levodopa.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Neurology, Mitate Hospital, Tagawa, Japan. y-sato@ktarn.or.jp

    , ,

    Source

    The American journal of medicine 118:11 2005 Nov pg 1250-5

    MeSH

    Accidental Falls
    Aged
    Antiparkinson Agents
    Cohort Studies
    Female
    Follow-Up Studies
    Fractures, Spontaneous
    Hip Fractures
    Homocysteine
    Humans
    Hyperhomocysteinemia
    Immobilization
    Incidence
    Japan
    Levodopa
    Osteoporosis
    Parkinson Disease
    Proportional Hazards Models
    Risk Factors

    Pub Type(s)

    Journal Article

    Language

    eng

    PubMed ID

    16271909

    Citation

    Sato, Yoshihiro, et al. "Homocysteine as a Predictive Factor for Hip Fracture in Elderly Women With Parkinson's Disease." The American Journal of Medicine, vol. 118, no. 11, 2005, pp. 1250-5.
    Sato Y, Iwamoto J, Kanoko T, et al. Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson's disease. Am J Med. 2005;118(11):1250-5.
    Sato, Y., Iwamoto, J., Kanoko, T., & Satoh, K. (2005). Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson's disease. The American Journal of Medicine, 118(11), pp. 1250-5.
    Sato Y, et al. Homocysteine as a Predictive Factor for Hip Fracture in Elderly Women With Parkinson's Disease. Am J Med. 2005;118(11):1250-5. PubMed PMID: 16271909.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson's disease. AU - Sato,Yoshihiro, AU - Iwamoto,Jun, AU - Kanoko,Tomohiro, AU - Satoh,Kei, PY - 2004/11/16/received PY - 2005/01/25/accepted PY - 2005/11/8/pubmed PY - 2005/12/13/medline PY - 2005/11/8/entrez SP - 1250 EP - 5 JF - The American journal of medicine JO - Am. J. Med. VL - 118 IS - 11 N2 - PURPOSE: Incidence of hip fractures among elderly patients with Parkinson's disease is high. Recent studies have found that levodopa induces hyperhomocysteinemia in Parkinson's disease. Hyperhomocysteinemia is considered to be a risk factor for osteoporotic fractures in elderly men and women. Very high plasma homocysteine levels are a feature of homocystinuria, characterized by the early onset of osteoporosis. To determine the association between plasma homocysteine concentration and the risk of hip fracture in Parkinson's disease patients receiving levodopa, we prospectively studied a cohort of elderly women with Parkinson's disease. METHODS: We studied 199 elderly women with Parkinson's disease receiving levodopa therapy, from whom blood samples had been obtained to measure plasma homocysteine. Age-adjusted incidence rates of hip fractures were calculated for quartiles of plasma homocysteine concentrations. Cox proportional-hazard regression was used to calculate hazard ratios for quartiles of homocysteine values. RESULTS: The mean duration of follow-up was 4.9 years. Hip fractures occurred in 66 patients. The age-adjusted incidence rates per 1000 person-years for hip fractures, from the lowest to the highest quartile of plasma homocysteine levels, were 1.59 (95% confidence interval [CI], 1.01-2.24), 1.57 (95% CI, 0.98-2.19), 1.21 (95% CI, 0.61-1.72), and 26.98 (95% CI, 16.48-37.24). The risk of hip fractures was greater in the highest quartile than that in the lowest, and the risk was almost 2.4 times higher. CONCLUSION: These findings suggest that the homocysteine concentration is an important risk factor for hip fractures in Parkinson's disease patients receiving levodopa. SN - 1555-7162 UR - https://www.unboundmedicine.com/medline/citation/16271909/Homocysteine_as_a_predictive_factor_for_hip_fracture_in_elderly_women_with_Parkinson's_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9343(05)00151-8 DB - PRIME DP - Unbound Medicine ER -